Insider Selling: Diaceutics (LON:DXRX) Insider Sells £950,000 in Stock

Diaceutics PLC (LON:DXRX) insider Ryan Gerard Keeling sold 500,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of GBX 190, for a total transaction of £950,000.

Ryan Gerard Keeling also recently made the following trade(s):

• On Thursday, November 12th, Ryan Gerard Keeling sold 100,000 shares of Diaceutics stock. The stock was sold at an average price of GBX 190, for a total value of £190,000.

Diaceutics Price Performance

Shares of LON DXRX traded down GBX 1 during trading on Friday, hitting GBX 194. The company had a trading volume of 330,586 shares, compared to its average volume of 298,740. The stock has a fifty day simple moving average of GBX 188.20 and a two-hundred day simple moving average of GBX 160.85. Diaceutics PLC has a fifty-two week low of GBX 125 and a fifty-two week high of GBX 210. The firm has a market capitalization of £164.85 million, a price-to-earnings ratio of -606.25 and a beta of 0.88. The company has a quick ratio of 9.92, a current ratio of 2.55 and a debt-to-equity ratio of 5.40.

Diaceutics (LON:DXRX) last issued its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. On average, research analysts expect that Diaceutics PLC will post 1.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of GBX 215.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.